VIRAL HEPATITIS B IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ОVERVIEW)
https://doi.org/10.22625/2072-6732-2017-9-4-24-30
Abstract
The review presents current data on the role of viral hepatitis B in on-cohematological patients. Possible ways of infection, prophylaxis of infection and activation of hepatitis B in this category of patients are considered. Specific features of the course of hepatitis B in various clinical situations are described: against the background of other viral infections and in the conduct of specific anti-leukemia therapy. The need to identify occult (occult) hepatitis in donors and patients with hemoblastosis is emphasized and methods for its detection are considered.
About the Authors
V. N. Chebotkevich
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
S. S. Bessmeltsev
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
V. V. Danilchenko
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
E. I. Kajtandzhan
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
V. V. Burylev
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
E. E. Kiseleva
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
A. V. Chechetkin
Russian Science Research Institute of Hematology and Transfusiology.
Russian Federation
Saint-Petersburg.
Russian Federation
Saint-Petersburg.
References
1. Hepatitis B. Fact sheet WHO, July 2017. – Available from: http://www.who.int/mediacentre/factsheets/fs204/ru/. [cited 2017 Aug30].
2. Bessmeltsev S.S., Abdulkadyrov K.M. Ultrasonic diagnostics in hematological practice. Saint-Petersburg: «KN»; 1997 (In Russian).
3. Bessmeltsev S.S., Abdulkadyrov K.M. Multiple Myeloma: Guidelines for Physicians. Moscow: МК, 2016 (In Russian).
4. Bessmeltsev S.S., Romanenko N.A. Anemia in tumorous diseases of the blood system: a guide for doctors: Guidelines for Physicians. Moscow: Special Publishing House of Medical Books, 2017 (In Russian).
5. Bessmeltsev S.S., Abdulkadyrov K.M. Vestnik Gematologii. 2006; 2 (2): 5-10 (In Russian).
6. Davydov M.I., Dmitrieva N.V. Infections in oncology. Moscow: Practical medicine, 2009. Poddubnaja I.V. Infection in patients with hematological malignancies; p. 114-23 (In Russian).
7. Bubnova L.N., Matveeva T.A., Berkos M.V. et al. Transfuziologija. 2016; 17 (2), Suppl. 1: 9-10 (In Russian).
8. Isakov V.A., Arhipova E.I., Isakov D.V. Herpesvirus infections. Saint-Petersburg: Publishing house SpetsLit; 2013 (In Russian).
9. Kornienko M.N., Rybalkina T.N., Karazhas N.V.et al. Jepidemiologija i infekcionnye bolezni. 2015; 20 (6): 33-8 (In Russian).
10. Chechetkin A.V., Danilchenko V.V., Makeev A.B. et al. Zhurnal infektologii. 2016; 8 (2), Supply: 102 (In Russian).
11. Tarasenko O.A., Gukasjan I. A., Sobolevskaja L.V., ChernenkoT.V. Spravochnik zavedujushhego KDL. 2011; 3: 3-8 (In Russian).
12. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV and HCV infections among antibody-negative blood donors by nucleic acid amplification testing. N. Engl. Med.2004 Aug; 351 (8): 760-8.
13. Vermeulen M, Coleman C, Walker E, et al. Transmission of occult HBV infection by ID-NAT screened blood. Vox Sang. 2014; 107 (Suppl. 1): 146-7.
14. Beljakova V.V. Sovershenstvovanie laboratornogo testirovanija dlj aobespechenija virusnoj bezopasnosti allogennyh gemokomponentov [Improving laboratory testing to ensure the viral safety of allogeneic hemocomponents] [author‘s abstract]. Moscow (Russia), 2015. 24 р. (In Russian).
15. O’Brien SF, Fearon MA, Yi QL, et al. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion. 2007 Oct; 47 (10): 1809-15.
16. TupolevaT.A., AbakarovR.R., Ignatova E.N. et al.Vestnik gematologii.2016; 12 (4): 56-7 (In Russian).
17. Tupoleva T.A., Romanova T.Ju., AbakarovR.R.et al. Laboratornye instrumenty obespechenija virusnoj bezopasnosti komponentov donorskoj krovi [Laboratory tools for ensuring the viral safety of donated blood components]. In: Molekuljarnaja diagnostika 2017 [Molecular diagnostics 2017]. Vol. 2. Moscow; 2017.P. 271-2 (In Russian).
18. Jesaulenko E.V., Suhoruk A.A., Ponjatishina M.V. et al. Zhurnal infektologii.2016; 8 (1): 66-72 (In Russian).
19. Gabdrahmanov I.A., Kozlov K.V., Zhdanov K.V. et al. Zhurnal infektologii. 2017; 9 (1): 107-9 (In Russian).
20. Schmeltzer P, Sherman K. Occult hepatitis B – clinical implications and treatment decisions. Dig. Dis. Sci. 2010 Dec; 55 (12): 3328-35.
21. Semenenko T.A., Jarosh P.V., Bazhenov A.I. et al. Jepidemiologija i vakcinoprofilaktika. 2012; 67: 9-14 (In Russian).
22. Feeney SA, McCaugheyС, Watt AP, et al. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J. Med.Virol. 2013 Apr; 85 (4): 597-601.
23. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003 Sep; 102 (5): 1930.
24. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, et al. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis В virus (HBV), single occult hepatitis С virus (HCV) and occult HBV and HCV dual infection. J. Med. Virol. 2007; 79 (3): 236-41.
25. Ostankova Ju.V., Semenov A.V. Vyjavlenie okkul›tnogo gepatita B pri nizkoj virusnoj nagruzke v perifericheskoj krovi HBsAg-negativnyh donorov krovi [Detection of occult hepatitis B with low viral load in the peripheral blood of HBsAg-negative blood donors]. In: Materialy XI s#ezda Vserossijskogo nauchnoprakticheskogo Obshhestva jepidemiologov, mikrobiologov i parazitologov «Obespecheniej epidemiologicheskogo blagopoluchija: vyzovy I reshenija» [XI Congress of the All-Russian Scientific and Practical Society of Epidemiologists, Microbiologists and Parasitologists «Ensuring Epidemiological Wellbeing: Challenges and Solutions»]. Saint-Petersburg (Russia): Research Institute of Epidemiology and Microbiology named after Pasteur, 2017. P. 310 (In Russian).
26. Dervite I, Hober D, Morel PN. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. Engl. J. Med. 2001 Jan; 344 (1): 68-9.
27. Vento S, Cainelli F, Longhi M. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 2002 Jun; 3 (6): 333-40.
28. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol.2005 Feb; 23 (4): 705-11.
29. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann. Hematol. 2004 Jan; 83 (1): 58-60.
30. Qawasmi M, Samuh M, Glebe D, et al. Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood. Hum Vaccin. Immunother. 2015; 11 (7): 1717-24.
31. Krymskij M.A., Krymskij R.M., Budanov M.V., Borisova V.N. Biofarmacevticheski jzhurnal. 2010; 2 (5): 8-15 (In Russian).
32. Semenenko T.A., Nikitina G. Ju., Jarosh L.V. et al. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2015; 17 (1): 73-8 (In Russian).
33. Ledin E.V. Jeffektivnost’ specificheskoj immunoprofilaktiki gepatita B u bol’nyh onkogematologicheskogo profilja [The effectiveness of specific immunoprophylaxis of hepatitis B in patients with hematological profile] [author’sabstract]. Moscow; 2008. 23 p. (In Russian).
34. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Ann Pharmacother.2002; 36 (7-8): 1219-29.
35. Poddubnaja I.V., Savchenko V.G. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow; 2016 (In Russian).
Review
For citations:
Chebotkevich V.N., Bessmeltsev S.S., Danilchenko V.V., Kajtandzhan E.I., Burylev V.V., Kiseleva E.E., Chechetkin A.V. VIRAL HEPATITIS B IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ОVERVIEW). Journal Infectology. 2017;9(4):24-30. (In Russ.) https://doi.org/10.22625/2072-6732-2017-9-4-24-30
Views:
885
.png)
.png)
Email this article 